Author Profile
Articles by this Author
What “Forest Medicine” Tells Us About Science, Intuition, and Just Going Outside
Does all science need a green score? Why Dr. Li's "Forest Medicine" study scored a yellow 58 on Tessa, and what it teaches us about data vs. human intuition
Beyond the Gut Health Hype: Mapping Microbiome Diversity to Frailty and Longevity
Separating hype from science: A landmark study links gut microbiome diversity to frailty and mortality in older women, evaluated by our Tessa platform
How the Human Brain Maps Uncertainty and Prepares for the Unexpected
REsearchers looked at how the brain’s memory center uses sharp-wave ripples to map environmental uncertainty and speed up visual processing
Is Your Screen Stealing Your Sleep? Tessa Tears Down a Landmark eReader Study
Does evening blue light actually ruin your sleep? Siensemetrica’s AI tool Tessa tears down the landmark 2015 PNAS eReader study to separate fact from fiction.
Daily Multivitamins and Brain Aging: What the Latest COSMOS Data Tells Us
Is a daily multivitamin a waste of time or a brain booster? See how Harvard’s COSMOS trial scored an 80/100 on Tessa for proving it slows cognitive aging.
Beyond the “Cure-All” Hype: Re-Engineering Cannabis to Treat Brain Injuries
Beyond the CBD hype: Scientists re-engineer cannabis compound CBN to protect the brain from injury and treat conditions like Alzheimer’s. See the data audit
Can a Common Joint Supplement Accelerate Alzheimer’s Progression?
Is glucosamine safe for dementia patients? Tessa analyzes a new study linking the popular joint supplement to accelerated Alzheimer’s disease progression.
Painting vs. Pilates: Can a Museum Match the Longevity Benefits of the Gym?
Painting vs. Pilates: Can art match the longevity benefits of the gym? See what epigenetic data reveals in this scientific review by Siensmetrica’s Tessa.
Beyond the Scale: The Growing Link Between GLP-1s and Mental Health
Do GLP-1s improve mental health? Tessa AI reviews the Swedish national cohort study on semaglutide & depression, giving it a reliable Green TScore of 78.
Evaluating the Breakthrough Semaglutide Study on Alcohol Use Disorder
Category: Clinical Research Transparency / GLP-1 Trends The buzz surrounding GLP-1 receptor agonists like semaglutide is undeniable. While initially celebrated for diabetes management and weight loss, headlines are now flooded with its potential to treat everything from dementia to addiction. But in an era of rapid scientific publishing and high media noise, how do clinicians, researchers, and stakeholders know which studies are truly foundational and which require a second look? One of the most talked-about recent studies: "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial" published in The [keep reading...]
